🤝 They will partner with Avid Bioservices for scaling up production. CHO Plus is also selected for the 2025 BTI Accelerator, aiding growth in life sciences.
💰 The program supports innovation, offering mentorship and a chance for $300,000 in non-dilutive funding.
Introduction:
The article discusses recent developments from CHO Plus, focusing on their new funding agreements and participation in a prominent accelerator program aimed at enhancing biopharmaceutical production capabilities. These initiatives underscore the company’s commitment to advancing monoclonal antibody production using engineered Chinese hamster ovary (CHO) cell lines, which are critical in therapeutic applications, particularly for combating virulent filoviruses.
- CHO Plus has secured a project agreement with BARDA’s BioMaP-Consortium, amounting to $10.4 million for the development of high-productivity CHO cell lines to manufacture monoclonal antibodies targeting filoviruses over a 30-month timeframe.
- The company aims to leverage its engineered cell lines for the effective production of monoclonal antibodies against highly contagious and lethal filoviruses, a critical need in biomedical research and response.
- In conjunction with its cell line development, CHO Plus will collaborate with Avid Bioservices to ensure scalability in monoclonal antibody production to meet industrial demands.
- CHO Plus has also been selected for the 2025 BioTools Innovator Accelerator, which supports life science startups through mentorship and funding, significantly enhancing its position in the biopharmaceutical landscape.
- The BTI Accelerator is designed to aid early-stage companies like CHO Plus by providing tailored mentorship, investor exposure, and opportunities to compete for substantial cash prizes, further facilitating the commercialization of their advancements in biologics production.
Conclusion:
These recent developments highlight CHO Plus’s strategic advancements in monoclonal antibody production, showcasing not only their technical capabilities but also their proactive engagement in critical partnerships and accelerator programs. The implications of their work could lead to enhanced therapeutic options for infectious diseases, paving the way for future innovations in biomanufacturing and therapeutic responses.
